Clinical Trial Update: Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of glofitamab and chidamide for recurrent or refractory diffuse large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Glofitamab (glofitamab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory | Phase 2 | Status: RECRUITING